^
    Back
    Association details:
    Biomarker:ARID1A mutation
    Cancer:Ovarian Cancer
    Drug:NXP800 (GCN2 activator)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    Nuvectis Pharma Press Release
    Title:

    FDA Grants Fast Track Designation to Nuvectis Pharma's NXP800 for the Treatment of Platinum-Resistant, ARID1A-Mutated Ovarian Carcinoma

    Published date:
    12/01/2022
    Excerpt:
    Nuvectis Pharma, Inc...announced that the U.S. Food and Drug Administration (the "FDA") has granted Fast Track Designation to NXP800 for the treatment of platinum-resistant, ARID1A-mutated ovarian carcinoma.
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer

    Excerpt:
    ...- Subjects with the following ARID1a mutated, ovarian/fallopian tube/primary peritoneal cancer histologies (ARID1a mutation status determined by a DNA-based Next Generation Sequencing test):...
    Trial ID:
    NXP800-101